FIELD: chemistry.
SUBSTANCE: present group of inventions refers to adoptopathy. Disclosed are chimeric receptors of antigen (CAR) containing a mesothelial-binding domain, as well as nucleic acids, a vector and a cell coding them. What is also presented is a method for producing T-cells and cell populations, as well as methods for providing anticancer immunity and methods of treating a disease associated with mesotheliene expression.
EFFECT: this group of inventions can find further application in cancer therapy.
92 cl, 48 dwg, 17 tbl, 18 ex
Title | Year | Author | Number |
---|---|---|---|
TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
METHODS OF PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2019 |
|
RU2822196C2 |
COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
Authors
Dates
2020-02-20—Published
2014-12-19—Filed